Navigation Links
Clinical Study With Investigational Cream Aims To Help Women Who Experience Painful Sex
Date:9/4/2012

NEW YORK, Sept. 4, 2012 /PRNewswire/ -- NeoGyn Vulvar Soothing Cream is sponsoring a clinical study held in four medical centers throughout the United States to test the effectiveness of an investigational cream.

(Photo: http://photos.prnewswire.com/prnh/20120717/NY41829 )

The study is being conducted at The Centers for Vulvovaginal Disorders in Washington DC, Pelvic & Sexual Health Institute in Philadelphia, PA, San Diego Sexual Medicine in San Diego, CA and Arizona Vulva Clinic. Additional applicants are needed for each location to participate in the randomized, double- blind, placebo controlled Research Study to evaluate a vulvar soothing cream containing cutaneous lysate for vulvar use.

Provoked vestibulodynia is classified as spontaneous pain in the vulvar region. The condition is typically characterized by pain at the entry point into the vagina during tampon insertion or sexual intercourse. Causes of provoked vestibulodynia can vary, which contributes to making it difficult for doctors to diagnose and treat this condition.

Each three month study will be led by physicians specialized in the field of women's health and vulvar care including, Dr. Andrew Goldstein, MD, Dr. Kristene Whitmore, MD and Dr. Susan Kellogg PhD, Dr. Irwin Goldstein, MD, and Dr. Joseph Brooks, MD. After inclusion, participants will attend one follow-up clinic visit, two telephone interviews and complete several questionnaires over the course of the study. The study cream and other study related tests, procedures and visits will be provided at no cost to each selected participant.

Eligible applicants are women who live in close proximity to the study sites and are 20-55 years old. Participants cannot be pregnant or breast-feeding and should be in a heterosexual relationship where a reliable form of birth control is being used. Pain experienced with the use of tampons or from intercourse are the top pre-requisites along with no medical history of heart disease, HIV, hepatitis B or C, or being post- menopausal.

NeoGyn's sponsorship of this clinical trial demonstrates the company's commitment to search for solutions in helping women with vulvar pain. The company's mission is also to help educate women and physicians on this not uncommon condition. NeoGyn encourages women to remain persistent in their quest for an accurate diagnosis and solution for vulvodynia

For more information about this clinical study or to see if you qualify, visit http://www.neogynstudy.org. For more information on vestibulodynia, visit http://www.neogyn.us, www.vaginalpainhelp.com, or www.nva.org.


'/>"/>
SOURCE NeoGyn
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
2. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
3. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
4. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
5. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. New Clinical Endocrinology Guidelines Support Lp-PLA2 Measurement For Risk Assessment of Coronary Artery Disease
8. First Patient Treated in U.S. Clinical Study of Cohera Medicals TissuGlu® Surgical Adhesive
9. Michael J. Fox Foundation-Funded Study Identifies Best Dyskinesia Clinical Rating Scale
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... YORK , April 19, 2017 The Mobile ... to showcase a healthy CAGR during the forecast period ... type in the global digital mobile X-Ray devices market, which ... Mn in 2017, expanding at a CAGR of 7% over ... absolute $ opportunity of more than US$ 100 Mn in ...
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt ... the first patients in Nashville , ... the Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) ... designed to provide long-term reflux control by restoring normal ... affects nearly 65 million people in the ...
(Date:4/19/2017)...  New research provides evidence that an old drug may ... study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... disease, the oral drug levodopa has long been considered the ... the disease progresses, the effects of the medication can partially ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor that ... his presence to an educational purpose as the host of the “Informed” series. The ... In a recent episode, the series focuses on thyroid cancer. , Although thyroid cancer ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... in Incentives, Rewards, and Recognition: A Nudge Guide," a groundbreaking analysis of how ... Offering practical takeaways to apply immediately to IRR programs, the report highlights proven ...
(Date:4/27/2017)... ... April 27, 2017 , ... Last night, ... CAREGiverSM of the Year for her extraordinary compassion and lifelong dedication to serve ... American professional caregivers for the prestigious award each year – identifying a CAREGiver ...
(Date:4/27/2017)... ... 2017 , ... Are you investing in the safety of your friends and ... the summer. While most of us assume this type of accident will never happen ... people are taking the time to learn how to respond effectively or prevent these ...
(Date:4/26/2017)... ... ... Journal of Oral Implantology – Tooth loss is not simply an ... complications with speech, eating, and overcompensation of mouth due to the deficiency. To combat ... number of tooth replacements increase, it is imperative to design an implant that will ...
Breaking Medicine News(10 mins):